Gregory Weinhoff Sells 73,196 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Gregory Weinhoff sold 73,196 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider directly owned 65,925 shares in the company, valued at $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Centessa Pharmaceuticals Stock Down 3.3%

NASDAQ CNTA traded down $0.89 during mid-day trading on Friday, hitting $26.33. The company’s stock had a trading volume of 1,362,238 shares, compared to its average volume of 1,141,428. The company’s 50 day simple moving average is $24.69 and its 200 day simple moving average is $24.24. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $9.60 and a twelve month high of $30.58. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $3.85 billion, a price-to-earnings ratio of -14.39 and a beta of 1.55.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on CNTA shares. B. Riley Financial lifted their price objective on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a report on Monday, December 1st. Wells Fargo & Company upped their target price on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Wolfe Research initiated coverage on Centessa Pharmaceuticals in a research note on Tuesday, February 24th. They set an “outperform” rating and a $40.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Finally, Oppenheimer increased their price objective on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Buy” and a consensus price target of $39.80.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Virtus Investment Advisers LLC boosted its stake in shares of Centessa Pharmaceuticals by 6.2% in the 4th quarter. Virtus Investment Advisers LLC now owns 10,034 shares of the company’s stock worth $251,000 after buying an additional 583 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 4.8% in the second quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock valued at $252,000 after acquiring an additional 870 shares in the last quarter. Coastal Bridge Advisors LLC grew its holdings in shares of Centessa Pharmaceuticals by 7.1% in the fourth quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock valued at $351,000 after acquiring an additional 931 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Centessa Pharmaceuticals by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock valued at $117,000 after acquiring an additional 979 shares during the last quarter. Finally, TD Waterhouse Canada Inc. bought a new stake in Centessa Pharmaceuticals during the fourth quarter worth $25,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.